放射性膀胱炎高压氧治疗后的患者报告结局:高压氧治疗多中心注册研究的早期结果
该研究分析高压氧治疗多中心注册联盟前瞻性收集的470例放射性膀胱炎患者数据,比较治疗开始与结束一周内的患者报告结局。高压氧治疗后血尿评分、泌尿困扰量表评分及生活质量评分均改善;基线血尿评分较高、吸烟史及非前列腺癌病史与血尿改善概率较低相关。
要点
- 高压氧治疗后RTOG血尿评分从2分降至0分(P < .001),泌尿困扰量表评分从33.3降至22.2(P < .001)。
- 生活质量EuroQol五维五水平评分从0.83升至0.85(P < .001)。
- 基线血尿评分较高、吸烟史及非前列腺癌病史与血尿改善概率较低相关。
核心结论
- 高压氧治疗放射性膀胱炎可改善患者报告的血尿、泌尿功能及生活质量。
- 基线血尿评分较高、吸烟史及非前列腺癌病史与血尿改善概率较低相关。
研究设计与样本
- 分析高压氧治疗多中心注册联盟前瞻性收集的数据,纳入470例放射性膀胱炎患者,比较治疗开始与结束一周内的患者报告结局。
主要发现
- 患者中位年龄73岁(IQR 12),中位高压氧治疗39次(IQR 10),放疗后中位年数5年(IQR 8)。
- 84%的患者(393/470)为前列腺癌相关放疗。
- EuroQol五维五水平评分从0.83(IQR 0.14)升至0.85(IQR 0.22),P < .001。
- 370例有完整RTOG血尿评分的患者,评分从2(IQR 2)降至0(IQR 2),P < .001。
- 246例有完整泌尿困扰量表简表评分的患者,评分从33.3(IQR 44)降至22.2(IQR 33),P < .001。
关键数值与推荐
- 在治疗前有可见血尿的患者中,回归分析显示较高的高压氧治疗血尿评分与较低的改善概率相关(OR 0.44,95% CI 0.26-0.73;P < .01)。
- 吸烟史与较低的改善概率相关(OR 0.44,95% CI 0.21-0.92;P = .03)。
- 非前列腺癌病史与较低的改善概率相关(OR 0.32,95% CI 0.10-0.99;P = .05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to determine changes in patient-reported hematuria and urinary symptoms after hyperbaric oxygen (HBO2) treatment for radiation cystitis (RC). MATERIALS AND METHODS: We analyzed prospectively collected data from the Multicenter Registry for Hyperbaric Oxygen Therapy Consortium accumulated within a week of beginning and ending HBO2. Measures included the modified Radiation Therapy Oncology Group (RTOG) Hematuria Scale, Urinary Distress Inventory Short Form, and EuroQol Five Dimension Five Level instrument. RTOG hematuria and Urinary Distress Inventory Short Form scores were compared using the sign test. Logistic regression was used to evaluate characteristics associated with hematuria improvement. RESULTS: A total of 470 registry patients had RC. The median age, number of HBO2 sessions, and years after radiation were 73 (IQR 12) years, 39 (IQR 10) sessions, and 5 (IQR 8) years, respectively. Eighty-four percent of patients (393/470) had prostate cancer‒related radiation. EuroQol Five Dimension Five Level scores improved from 0.83 (IQR 0.14) to 0.85 (IQR 0.22; P < .001. Three hundred seventy patients had complete RTOG hematuria scores that improved from 2 (IQR 2) to 0 (IQR 2; P < .001. Two hundred forty-six patients had complete Urinary Distress Inventory Short Form ratings that decreased from 33.3 (IQR 44) to 22.2 (IQR 33; P < .001). Regression analysis of those with visible hematuria before HBO2 showed lower improvement odds associated with higher HBO2 hematuria scores (odds ratio [OR] 0.44, 95% CI 0.26-0.73; P < .01), a smoking history (OR 0.44, 95% CI 0.21-0.92; P = .03), or a nonprostate cancer history (OR 0.32, 95% CI 0.10-0.99; P = .05). CONCLUSIONS: HBO2 for RC improved reported hematuria, urinary function, and quality of life. Higher baseline hematuria scores, smoking, and nonprostate cancer history were associated with lower odds of hematuria improvement.
引用
- Moses RA, Hunter AE, Brandes ER, et al. Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy. J Urol. 2024. PMID: 38573938. doi:10.1097/JU.0000000000003929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。